IRIS
Cento, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.011
AS - Asia 2.682
EU - Europa 892
SA - Sud America 599
AF - Africa 138
OC - Oceania 1
Totale 8.323
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.939
SG - Singapore 1.647
BR - Brasile 486
CN - Cina 472
VN - Vietnam 271
FI - Finlandia 186
IE - Irlanda 144
IT - Italia 132
DE - Germania 98
FR - Francia 61
NG - Nigeria 59
GB - Regno Unito 57
SE - Svezia 55
HK - Hong Kong 47
IN - India 43
AR - Argentina 41
NL - Olanda 41
BD - Bangladesh 37
MX - Messico 26
ZA - Sudafrica 26
CA - Canada 23
EC - Ecuador 22
IQ - Iraq 21
JP - Giappone 19
PL - Polonia 19
RU - Federazione Russa 19
TR - Turchia 19
BE - Belgio 15
ET - Etiopia 15
ID - Indonesia 14
CL - Cile 13
SA - Arabia Saudita 12
CO - Colombia 11
ES - Italia 11
UA - Ucraina 11
VE - Venezuela 10
MA - Marocco 9
PA - Panama 9
PH - Filippine 8
PK - Pakistan 8
PY - Paraguay 8
KE - Kenya 7
MY - Malesia 7
DO - Repubblica Dominicana 6
JO - Giordania 6
AT - Austria 5
AZ - Azerbaigian 5
BH - Bahrain 5
DZ - Algeria 5
EG - Egitto 5
KZ - Kazakistan 5
AM - Armenia 4
BG - Bulgaria 4
CM - Camerun 4
CZ - Repubblica Ceca 4
IL - Israele 4
LV - Lettonia 4
NP - Nepal 4
PE - Perù 4
UZ - Uzbekistan 4
BO - Bolivia 3
DK - Danimarca 3
EE - Estonia 3
GR - Grecia 3
JM - Giamaica 3
KG - Kirghizistan 3
MD - Moldavia 3
PT - Portogallo 3
RO - Romania 3
CR - Costa Rica 2
GE - Georgia 2
HR - Croazia 2
IR - Iran 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
HN - Honduras 1
KW - Kuwait 1
KY - Cayman, isole 1
LB - Libano 1
LU - Lussemburgo 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TM - Turkmenistan 1
UY - Uruguay 1
Totale 8.323
Salva come PNG Salva come JPEG
Città #
Dallas 865
Singapore 664
Ashburn 529
Chandler 399
San Jose 397
The Dalles 279
Shanghai 218
Helsinki 185
Dublin 144
Boardman 140
New York 117
Beijing 91
Ho Chi Minh City 77
Lawrence 72
Princeton 72
Hanoi 68
Los Angeles 64
Benin City 59
Council Bluffs 46
Hong Kong 45
Paris 36
São Paulo 35
Amsterdam 31
Santa Clara 30
Bari 24
London 22
Milan 21
Falkenstein 20
Seattle 20
Da Nang 18
Pune 16
Rome 16
Haiphong 15
Johannesburg 15
Rio de Janeiro 15
Tokyo 15
Phoenix 14
Warsaw 14
Brussels 13
Munich 13
Wilmington 13
Chicago 12
Guayaquil 12
Addis Ababa 11
Boston 11
Brooklyn 11
Ribeirão Preto 11
San Francisco 11
Orem 10
Atlanta 9
Belo Horizonte 9
Brasília 9
Campinas 9
Montreal 9
Stockholm 9
Assago 8
Baghdad 8
Naples 8
Ankara 7
Ann Arbor 7
Cagliari 7
Chennai 7
Curitiba 7
Frankfurt am Main 7
Guarulhos 7
Moscow 7
Alessandria 6
Bắc Ninh 6
Fortaleza 6
Mexico City 6
Quito 6
Salvador 6
Sorocaba 6
Toronto 6
Amman 5
Baku 5
Caracas 5
Casablanca 5
Charlotte 5
Dhaka 5
Guarujá 5
Istanbul 5
Jeddah 5
Jundiaí 5
Nairobi 5
Poplar 5
Santiago 5
São Gonçalo 5
Thái Nguyên 5
Aracaju 4
Buffalo 4
Denver 4
Durban 4
Lahore 4
Manama 4
Nova Iguaçu 4
Petrópolis 4
Ponta Grossa 4
Porto Seguro 4
Quảng Ngãi 4
Totale 5.337
Salva come PNG Salva come JPEG
Nome #
What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? 426
Endonasal filters for the prevention and control of respiratory allergy and infections. A multi-stakeholder assessment 343
Real life experiences in HCV management in 2018 102
Beyond the distance between juridic and scientific decision-making process: An evidence-based prediction algorithm for professional liability assessment in healthcare-associated infections 96
Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 89
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 86
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs 85
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs 84
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 84
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 83
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 82
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 79
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy 78
Back to the future (of common respiratory viruses) 75
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 75
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions 75
Biotech innovations in the prevention of respiratory infectious diseases 74
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 73
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures 73
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 71
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 71
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 68
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 68
CLINICAL RELEVANCE OF NEXT GENERATION SEQUENCING ON BASELINE DETECTION OF MINORITY RESISTANCE ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE INHIBITORS 68
CLINICAL RELEVANCE OF ACCURATE HCV GENOTYPE AND SUBTYPE ASSIGNMENT BY NS3/NS5A/NS5B DIRECT SEQUENCING IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS 65
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 65
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 64
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 64
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 64
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 63
BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES 63
Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model 63
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon 63
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 63
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 63
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 62
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 62
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 62
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 61
Epidemiology and Resistance Profiles of Bacteria Isolated From Blood Samples in Septic Patients at Emergency Department Admission: A 6-Year Single Centre Retrospective Analysis From Northern Italy 61
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 61
In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract 60
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 60
CHARACTERISTICS OF LAMIVUDINE RESISTANCE PROFILES IN HBV REVERSE TRANSCRIPTASE FROM A NATIONAL COLLABORATIVE STUDY OF HIV plus HBV INFECTED INDIVIDUALS ON LONG-EXPOSURE TO LAMIVUDINE INCLUDING REGIMENS 60
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 59
An overview of SARS-CoV-2 variants circulating in the 2020-2022 period in Lombardy 59
Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience 59
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 59
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 59
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 59
Human papillomaviruses 53 and 66: clinical aspects and genetic analysis 59
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 59
Clinical usefulness of HCV sequencing on clinical samples with different HCV-RNA levels 59
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 58
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 58
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality 58
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era 58
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 57
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study 57
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 57
CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING 56
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution 56
Biphasic kinetics of HCV-RNA decay and quasispecies evolution during DAA-treatment are associated with risk of virological failure 56
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine 56
Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release 55
The use of human immunodeficiency virus resistance tests in clinical practice 54
Resistance to direct-acting antiviral agents: clinical utility and significance 54
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 53
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents 53
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 53
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? 52
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users 51
HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION 51
Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance 51
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 51
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 51
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV QUANTIFICATION WITHIN BLOOD AND LIVER SAMPLES (TUMORAL AND NON TUMORAL TISSUES) OF HCC/TRANSPLANTED PATIENTS 50
Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy 50
KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE 49
KEY PATTERNS OF HBsAg MUTATIONS CORRELATE WITH MECHANISMS UNDERLYING LEVELS OF SERUM HBV DNA 49
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 49
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety 49
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 49
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C 48
KEY PATTERNS OF HBX AND PRE-S1/S2 MUTATIONS ARE INVOLVED IN MECHANISMS UNDERLYING HBV-INDUCED HEPATOCELLULAR CARCINOMA IN VIVO 48
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics 48
Early detection of NS3-resistance in HCV patients with advanced disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing 48
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population 48
High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction 48
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 48
Viral Respiratory Infections: New Tools for a Rapid Diagnosis 48
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology 47
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 47
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 47
Increase in invasive group A streptococcal infections in Milan, Italy: a genomic and clinical characterization 46
Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification 45
CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR 44
HCV GENOTYPES HAVE DIFFERENT GENETIC BARRIERS IN THE GENERATION OF RESISTANCE MUTATIONS TO PROTEASE INHIBITORS IN ADVANCED CLINICAL DEVELOPMENT 44
Fast and deep early HCV-RNA decay is accompanied by fast aminotransferases normalization values in cirrhotic HCV-1 patients treated with paritaprevir/r-ombitasvir and dasabuvir with ribavirin: a potential role of baseline major resistance mutations 44
OVERLAPPING STRUCTURE OF HBV GENOME AND IMMUNE SELECTING PRESSURE ARE THE MAIN DRIVING FORCES FOR HBV EVOLUTION 43
Totale 6.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.181
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 2 1 0
2021/2022104 0 1 0 3 1 0 1 2 6 4 77 9
2022/20231.183 149 15 97 120 79 103 0 129 220 101 161 9
2023/20241.148 77 121 258 82 45 175 70 64 16 36 98 106
2024/20251.508 27 4 6 38 28 181 64 75 289 379 183 234
2025/20264.450 585 504 761 388 174 265 1.241 168 211 153 0 0
Totale 8.416